Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Merck (NYSE: MRK) announced that the CDC's Advisory Committee on Immunization Practices (ACIP) has recommended ENFLONSIA™ for preventing RSV lower respiratory tract disease in infants under 8 months of age. ENFLONSIA, recently FDA-approved, is the first and only RSV preventive option using the same dose regardless of infant weight.
The preventive monoclonal antibody provides protection through 5 months, covering a typical RSV season. Notably, ENFLONSIA has been included in the Vaccines for Children Program, enhancing accessibility. Merck plans to begin taking orders in July 2025, with deliveries scheduled before the 2025-2026 RSV season.
Merck (NYSE:MRK) has announced a virtual investor event scheduled for July 17, 2025, at 9:00 a.m. ET. During this event, the company's scientific and commercial team leaders will present an overview of Merck's advancing research pipeline focused on HIV treatment and prevention.
The presentation will be accessible via webcast to investors, analysts, media representatives, and the general public. Institutional investors and analysts will have the opportunity to participate in a Q&A session by dialing in using the provided information.
FAQ
What is the current stock price of Merck & Co (MRK)?
What is the market cap of Merck & Co (MRK)?
